Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis
1.5 Data validation
1.6 Data Sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Nanomedicine industry 3600 synopsis, 2018 – 2032
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Modality trends
2.1.4 Application trends
2.1.5 Indication trends
2.1.6 Molecule type trends
Chapter 3 Nanomedicine Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing adoption of nanotechnology-based methods for drug delivery
3.2.1.2 Increasing prevalence of infectious diseases
3.2.1.3 Technological advancements in nanotechnology
3.2.1.4 Increasing aging population
3.2.2 Industry pitfalls & challenges
3.2.2.1 High development costs
3.2.2.2 Manufacturing complexities
3.3 Growth potential analysis
3.3.1 By modality
3.3.2 By application
3.3.3 By indication
3.3.4 By molecule type
3.4 COVID- 19 impact analysis
3.5 Porter's analysis
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players, 2022
4.4 Competitive positioning matrix, 2022
4.5 Strategy dashboard, 2022
4.6 Strategic outlook matrix, 2022
Chapter 5 Nanomedicine Market Size and Forecast, By Modality (USD Million)
5.1 Key trends, by modality
5.2 Treatment
5.3 Diagnostics
Chapter 6 Nanomedicine Market Size and Forecast, By Application (USD Million)
6.1 Key trends, by application
6.2 Drug delivery
6.3 In vitro diagnostics
6.4 Implants
6.5 Vaccines
6.6 In vivo imaging
6.7 Other applications
Chapter 7 Nanomedicine Market Size and Forecast, By Indication (USD Million)
7.1 Key trends, by indication
7.2 Oncology
7.3 Infectious diseases
7.4 Cardiovascular diseases
7.5 Orthopedic diseases
7.6 Neurological diseases
7.7 Other indications
Chapter 8 Nanomedicine Market Size and Forecast, By Molecule Type (USD Million)
8.1 Key trends, by molecule type
8.2 Nanoparticles
8.2.1 Metal & metal oxide nanoparticles
8.2.2 Liposomes
8.2.3 Polymers & polymer drug conjugates
8.2.4 Hydrogel nanoparticles
8.2.5 Dendrimers
8.2.6 Inorganic nanoparticles
8.3 Nanotubes
8.4 Nanodevices
8.5 Nanoshells
Chapter 9 Nanomedicine Market Size and Forecast, By Region (USD Million)
9.1 Key trends, by region
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Switzerland
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East & Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of Middle East & Africa
Chapter 10 Company Profiles
10.1 Sanofi SA
10.2 Celgene Corporation
10.3 Nanobiotix
10.4 Luminex Corporation
10.5 Nanospectra Biosciences, Inc.
10.6 NanoCarrier Co. Ltd.
10.7 Johnson & Johnson Services, Inc.
10.8 Merck & Co., Inc.
10.9 Pfizer, Inc.
10.10 NanoCarrier Co. Ltd.
10.11 Taiwan Liposome Company Ltd.
10.12 Hoffmann-La Roche AG(Roche)
10.13 Gilead Science Inc.
10.14 Ipsen SA
